A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects
Status:
Completed
Trial end date:
2012-01-26
Target enrollment:
Participant gender:
Summary
This first time in human (FTIH) study will be the first administration of GSK1322322 as an
intravenous formulation and will investigate safety, tolerability, and pharmacokinetics in
healthy subjects. One cohort of subjects will undergo bronchoalveolar lavage (BAL) for
determination of GSK1322322 concentrations in lung with simultaneous comparison to plasma
concentrations to evaluate drug penetration in the lung. The study will evaluate the absolute
bioavailability of an oral tablet formulation as compared to the IV formulation.In addition,
Amendment 01 will enable the investigation of an improved IV formulation (GSK1322322J
mesylate salt) in an additional repeat dosing cohort and the supra-therapeutic cohort.